(S)-2-苄氧基羰基氨基-4,4-二氟丁酸甲酯 | 342612-83-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-苄氧基羰基氨基-4,4-二氟丁酸甲酯
• 英文名称: methyl (S)-2-(((benzyloxy)carbonyl)amino)-4,4-difluorobutanoate
• 英文别名: (S)-2-Benzyloxycarbonylamino-4,4-difluoro-butyric acid methyl ester；methyl (2S)-4,4-difluoro-2-(phenylmethoxycarbonylamino)butanoate
• CAS: 342612-83-3
• 化学式: C₁₃H₁₅F₂NO₄
• 分子量: 287.263
• InChiKey: HVDKCIFFBKRSLO-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  (S)-2-苄氧基羰基氨基-4,4-二氟丁酸甲酯 在 二异丁基氢化铝 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以89%的产率得到benzyl (S)-(4,4-difluoro-1-oxobutan-2-yl)carbamate
  参考文献：
  名称：

  含氟氨基酸的有效手性合成：N-苄氧基羰基-2-氨基-4,4-二氟丁酸甲酯及其类似物

  摘要：

  以高对映体过量制备含氟氨基酸，N-苄氧基羰基-2-氨基-4,4-二氟丁酸甲酯和类似物。掺入2-氨基-4,4-二氟丁酸作为P1基团提供了有效的HCV NS3蛋白酶抑制剂。

  DOI：

  10.1016/j.tetlet.2007.11.163
• 作为产物：
  描述：

  (±)-Z-α-膦酰甘氨酸三甲酯 在 (+)-1,2-bis-[(2S,5S)-2,5-diethylphospholano]benzene (1,5-cycloctadiene)rhodium(I) trifluoromethanesulfonate 、 四甲基胍 作用下， 以 四氢呋喃 、 甲醇 为溶剂， -78.0 ℃ 、1.03 MPa 条件下， 反应 12.91h， 生成 (S)-2-苄氧基羰基氨基-4,4-二氟丁酸甲酯
  参考文献：
  名称：

  [EN] SELECTIVE KINASE INHIBITORS
  [FR] INHIBITEURS SÉLECTIFS DE KINASES

  摘要：

  提供了用于抑制Syk激酶的嘧啶化合物，用于制备这些化合物的中间体，其制备方法，药物组合物，抑制Syk激酶活性的方法，以及治疗至少部分由Syk激酶活性介导的疾病的方法。

  公开号：

  WO2013078468A1

文献信息

• QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS
  申请人：Nazaré Marc

  公开号：US20100135999A1

  公开（公告）日：2010-06-03

  The present invention relates to compounds of the formula I, in which R 1 ; R 2 ; R 3 ; R 4 ; R 5 ; R 6 ; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述声明中指示的含义。公式I的化合物是有价值的药理活性化合物。它们对血小板具有强烈的抗聚集作用，从而具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，通常适用于存在不良激活血小板ADP受体P2Y12的情况，或者治愈或预防需要抑制血小板ADP受体P2Y12的情况。此外，本发明还涉及制备公式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药制剂。
• Quinoline-carboxamide derivatives as P2Y12 antagonists
  申请人：Nazare Marc

  公开号：US08669266B2

  公开（公告）日：2014-03-11

  The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及公式I的化合物，其中R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G和M具有所述权利要求中指定的含义。公式I的化合物是有价值的药理活性化合物。它们在血小板上表现出强烈的抗聚集作用，因此具有抗血栓作用，适用于治疗和预防心血管疾病，如血栓栓塞病或再狭窄。它们是血小板ADP受体P2Y12的可逆拮抗剂，并且通常可以应用于存在不希望的血小板ADP受体P2Y12激活或需要抑制血小板ADP受体P2Y12的治疗或预防的情况。此外，本发明还涉及公式I的化合物的制备方法，它们的使用，特别是作为药物的活性成分，以及包含它们的药物制剂。
• Direct Bioisostere Replacement Enabled by Metallaphotoredox Deoxydifluoromethylation
  作者：Edna Mao、Cesar N. Prieto Kullmer、Holt A. Sakai、David W. C. MacMillan

  DOI：10.1021/jacs.3c14460

  日期：2024.2.28

  alternative would be to directly convert a functional group into its corresponding bioisostere at a late stage. Herein, we report the realization of this approach through the conversion of aliphatic alcohols into the corresponding difluoromethylated analogues via the merger of benzoxazolium-mediated deoxygenation and copper-mediated C(sp3)–CF2H bond formation. The utility of this method is showcased in a variety

  用相应的生物等排体替换官能团是药物发现活动中广泛采用的一种策略，它允许药物化学家在保持效力的同时改善候选物的 ADME 特性。然而，生物等排体的掺入通常需要对潜在候选物进行长时间的从头再合成，这代表了其更广泛评估的瓶颈。另一种方法是在后期直接将官能团转化为相应的生物等排体。在此，我们报道了通过苯并噁唑介导的脱氧和铜介导的 C（sp3）-CF2H 键形成的合并，将脂肪醇转化为相应的二氟甲基化类似物来实现这种方法。该方法的实用性在各种复合醇和药物化合物中得到展示。
• Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors
  作者：Pernilla Örtqvist、Shane D. Peterson、Eva Åkerblom、Thomas Gossas、Yogesh A. Sabnis、Rebecca Fransson、Gunnar Lindeberg、U. Helena Danielson、Anders Karlén、Anja Sandström

  DOI：10.1016/j.bmc.2006.11.003

  日期：2007.2.1

  Molecular modeling and inhibitory potencies of tetrapeptide protease inhibitors of HCV NS3 proposed phenylglycine as a new promising P2 residue. The results suggest that phenylglycine might be capable of interacting with the NS3 (protease-helicase/ NTPase) in ways not possible for the common P2 proline-based inhibitors. Thus, a series of tripeptides, both linear and macrocyclic, based on p-hydroxy-phenylglycine in the P2 position were prepared and their inhibitory effect determined. When the p-hydroxy group was replaced by methoxy, isoquinolin-, or quinolinyloxy functions, inhibitors with improved potencies were obtained. The P2 phenylglycine-based inhibitors were further optimized by C-terminal extension to acyl sulfonamides and by P1-P3 cyclization, which gave products with inhibition constants in the nanomolar range (similar to 75 nM). (c) 2006 Elsevier Ltd. All rights reserved.
• US8669266B2
  申请人：——

  公开号：US8669266B2

  公开（公告）日：2014-03-11